Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics

Biological Psychiatry

Volumn 39, Issue 4, 1996, Pages 249-254

  Szymanski, Sally ^a,e   Lieberman, Jeffrey ^b   Pollack, Simcha ^b,c   Kane, John M ^b   Safferman, Allan ^b   Munne, Raphael ^b   Umbricht, Daniel ^b   Woerner, Margaret ^b   Masiar, Stephen ^d   Kronig, Michael ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

^d Pilgrim Psychiatric Center   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clozapine; Gender; Medication levels; Prolactin; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; THERAPY RESISTANCE;

EID: 0029971823     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00138-7     Document Type: Article

References (19)

1. Angermeyer KC, Kuhn L (1988): Gender differences in age at onset of schizophrenia. Eur Arch Psychiatr Neurol Sci 237: 351-364.
2. Angermeyer KC, Kuhn L, Goldstein JM (1990): Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull 16(2):293-307.
3. Bowers MB, Swigas ME, Jatlow PI, Goicoechen N (1984): Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45(6):248-251.
4. DeLisi LE (1992): The significance of age of onset for schizophrenia. Schizophr Bull 18(2):209-215.
5. Fri CG, Wiesel FA, Sedvall G (1974): Simultaneous quantification of homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid by mass fragmentography. Life Sci 14: 2469-2480.
6. Goldstein JM (1988): Gender differences in the course of schizophrenia. Am J Psychiatry 145(6):684-689.
7. Guy W (1976): Clinical Global Impression Scale. EDCEU Assessment Manual. Washington, DC: U.S. Department of Health, Education and Welfare, pp 219-222.
8. Haring C, Meise U, Humpel C, Saria A, Fleishhacker WW, Hinterhuber H (1989): Dose-related plasma levels of clozapine: influence of smoking, behavior, sex and age. Psychopharmacol 99:538-540.
9. Kane JM, Cooper TB, Sacher EJ, Halpern FS, Bailine S (1981): Clozapine: plasma levels and prolactin response. Psychopharmacol 73:184-187.
10. Loebel AD, Lieberman JA, Alvir JMA, Geisler SH, Szymanski SR (1992): Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183-1188.
11. Meltzer HY, Busch DA, Fang VS (1983): Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9:271-283.
12. Meltzer HY, Goode DJ, Schyre PM, Young M, Fang VS (1979): Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136:1550-1555.
13. Murphy DL, Hamilton J (1984): Gender-related differences in neuropharmacologic responsivity: contributions from neurochemical and drug metabolism studies. Sex differences in response to psychopharmacological interventions in humans. Psychopharmacol Bull 14:526-530.
14. Nathan RS, Sacher EJ, Ostrow L, Asnis GM, Halbreich U, Halpern F, Renai NI, Slotnick V (1983): A preliminary study of sex-related differences in prolactin response to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients. Psychopharmacol 80:45-49.
15. Seeman MV (1986): Current outcome in schizophrenia: Women vs. men. Acta Psychiatr Scand 73:609-617.
16. Seeman M (1992): Gender differences in schizophrenia. Can J Psychiatry 27:108-111.
17. Simpson GM, Cooper TD (1979): Clozapine plasma levels and convulsions. Am J Psychiatry 135:99-100.
18. Simpson GM, Lee JH, Zoubek B (1979): A rating scale for tardive dyskinesia. Psychopharmacol 64:171-179.
19. Woerner MG, Mannuzza S, Kane JM (1988): Anchoring the Brief Psychiatric Rating Scale; an aid to improve reliability. Psychopharmacol Bull 24:112-117.